Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: Systematic review

International Journal of Tuberculosis and Lung Disease

Volumn 10, Issue 1, 2006, Pages 19-23

  Fraser, Abigail ^a   Paul, M ^a   Attamna, A ^b   Leibovici, L ^a,c  

^a RABIN MEDICAL CENTER   (Israel)

^b CLALIT HEALTH SERVICES   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Chemoprophylaxis; Multidrug resistant tuberculosis; Systematic review

Indexed keywords

ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; LEVOFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLONE; RIFAMPICIN;

BRONCHOSCOPY; CHEMOPROPHYLAXIS; COHORT ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; FOLLOW UP; HUMAN; LIVER INJURY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 33144458559     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Wilkinson D, Squire S B, Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials. Brit Med J 1998; 317: 625-629.
2. Smieja M J, Cook D J, Smaill F M. Isoniazid for preventing tuberculosis in non-HIV infected persons (Cochrane Review). In: The Cochrane Library. Issue 1. Chichester, UK: John Wiley & Sons Ltd, 2004.
3. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons (Cochrane Review). In: The Cochrane Library. Issue 1. Chichester, UK: John Wiley & Sons Ltd, 2004.
4. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161 (4 Pt 2): S221-S247.
5. Heldal E, Dahle U R, Sandven P, et al. Risk factors for recent transmission of Mycobacterium tuberculosis. Eur Respir J 2003; 22: 637-642.
6. Passannante M R, Gallagher C T, Reichman L B. Preventive therapy for contacts of multidrug-resistant tuberculosis. A Delphi survey. Chest 1994; 106: 431-434.
7. World Health Organization. Anti-tuberculosis drug resistance in the world. Report No 3. WHO/HTM/TB/2004.343. Geneva, Switzerland: WHO, 2004.
8. Pablos-Mendez A, Gowda D K, Frieden T R. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework. Bull World Health Organ 2002; 80: 489-500.
9. Schaaf H S, Gie R P, Kennedy M, Beyers N, Hesseling P B, Donald P R. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 2002; 109: 765-771.
10. Schaaf H S, Vermeulen H A, Gie R P, Beyers N, Donald P R. Evaluation of young children in household contact with adult multidrug-resistant pulmonary tuberculosis cases. Pediatr Infect Dis J 1999; 8: 494-500.
11. Kritski A L, Marques M J, Rabahi M F, et al. Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 1996; 153: 331-335.
12. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Helsinki, Finland: WMA, 2004. www.wma.net/e/policy/b3.htm Accessed May 2005.
13. Simone P M, Dooley S W. Multidrug-resistant tuberculosis, 1994. Atlanta, GA: Centers for Disease Control and Prevention, 1994. www.cdc.gov/nchstp/tb/ pubs/mdrtb/mdrtb.htm Accessed December 2004.
14. Ministry of Health. National program for the elimination of tuberculosis. Circular No. 3/97 of the Director General. Jerusalem, Israel: MOH, 30 March 1997 [in Hebrew].
15. Papastavros T, Dolovich L R, Holbrook A, Whitehead L, Loeb M. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ 2002; 167: 131-136.
16. Update: Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR 2003; 52: 735-739.